NASDAQ:REPLReplimune Group Stock Price, Forecast & News

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL stock has increased by 57.4% and is now trading at $18.78. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group.

Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, June 26th 2020. View our earnings forecast for Replimune Group.

Replimune Group Inc (NASDAQ:REPL) issued its quarterly earnings data on Thursday, February, 13th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.10. View Replimune Group's earnings history.

6 Wall Street analysts have issued 12-month price objectives for Replimune Group's stock. Their forecasts range from $12.50 to $30.00. On average, they expect Replimune Group's stock price to reach $23.58 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price. View analysts' price targets for Replimune Group.

Media coverage about REPL stock has been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Replimune Group earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutReplimune Group.

Replimune Group saw a increase in short interest in April. As of April 15th, there was short interest totaling 816,400 shares, an increase of 10.7% from the March 31st total of 737,300 shares. Based on an average trading volume of 82,500 shares, the short-interest ratio is presently 9.9 days. Currently, 6.0% of the shares of the stock are short sold. View Replimune Group's Current Options Chain.

Some companies that are related to Replimune Group include Novavax (NVAX), Fate Therapeutics (FATE), Alector (ALEC), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Regenxbio (RGNX), I-Mab (BDTX), Mesoblast (MESO), Twist Bioscience (TWST), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM) and Cortexyme (CRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Peabody Energy (BTUUQ), Myovant Sciences (MYOV), Pfizer (PFE), Fate Therapeutics (FATE), Immunomedics (IMMU), AbbVie (ABBV), Aerie Pharmaceuticals (AERI), Axsome Therapeutics (AXSM) and Cleveland-Cliffs (CLF).

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (8.13%), BlackRock Inc. (2.84%), Emerald Advisers LLC (2.17%), Emerald Mutual Fund Advisers Trust (2.13%), Victory Capital Management Inc. (1.22%) and Victory Capital Management Inc. (1.22%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, Joseph P Slattery, Philip Astley-Sparke and Robert Coffin. View institutional ownership trends for Replimune Group.

REPL stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Squarepoint Ops LLC, Morgan Stanley, Wells Fargo & Company MN, Emerald Mutual Fund Advisers Trust, Alps Advisors Inc., and Deutsche Bank AG. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Philip Astley-Sparke, and Robert Coffin. View insider buying and selling activity for Replimune Group.

REPL stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Nuveen Asset Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., Ensign Peak Advisors Inc, AQR Capital Management LLC, and UBS Group AG. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, and Joseph P Slattery. View insider buying and selling activity for Replimune Group.

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REPL stock can currently be purchased for approximately $18.78.

Replimune Group has a market capitalization of $688.29 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe.

The official website for Replimune Group is www.replimune.com.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]